These studies demonstrate that HDAC inhibitors reverse the radioresistance in prostate cancer through down‐modulation of USF‐1‐mediated transactivation of target genes involved in cell proliferation and cell cycle. This evidence concerns the gene HDAC9 and prostate cancer.